Messenger RNA is translated at the ribosome via tRNA docking and delivery of specific amino acids.
Messenger RNA is translated at the ribosome via tRNA docking and delivery of specific amino acids.

Tranosyl™ is a novel proprietary tRNA anti-sense technology platform to inhibit the growth and proliferation of cancer cells. Tranosyl has two components of selective toxicity. First, it targets over-expressed or unique cell surface proteins expressed specifically on cancerous cells. The second level of selective toxicity is achieved by targeting conserved portions of t-RNA, also known as the 28s-binding subunit of ribosomal RNA molecules (rRNA) contained therein.

Tranosyl technology involves the synthesis and delivery of complementary nucleotide strands designed to bind to the 5’ prime end of t-RNA - the site of t-RNA activation for reading messenger RNA (m-RNA) on ribosomes, a critical step in translation. Tranosyl™ also delivers biologically inactive amino acid residues, which will cause the t-RNA to be nonfunctional. This will eventually block all t-RNAs, particularly those involved in the production of "housekeeping" proteins. Interruption of housekeeping protein synthesis will lead ultimately to cell death by inducing self-directed apoptosis.